A new era may be dawning for drug manufacturers—one in which they transition from a world of jeopardy to one with double jeopardy.
Pharmaceutical companies have always faced the reality of losing billions on drugs that fail in late-stage clinical trials. Now there are new challenges: guaranteeing the performance of medications that have found a market and demonstrating value in emerging payment-reform models.
Read Full Article »